We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Next-Gen Products Driving Global POC Molecular Diagnostics Market

By LabMedica International staff writers
Posted on 31 Dec 2018
The global point of care (POC) molecular diagnostics market is expected to grow at a CAGR of close to 14% during the period 2019-2023, driven mainly by the growing number of M&As and collaborations, and rising focus on next-generation products.

These are the latest findings of Technavio Research, (London, UK), a global technology research and advisory company.

The growing number of M&As and collaborations is acting as a key growth driver of the global POC molecular diagnostics market. More...
Large companies have been increasingly acquiring and collaborating with specialized POC molecular diagnostic companies to expand their product portfolio. As a result, the parent companies have reduced their internal costs for product development, clinical study, and regulatory approvals.

The growing emphasis on technological advances will accelerate the growth of the global POC molecular diagnostics market. Advances in the field of information technology are providing ease of transmission by electronically recording and transferring the data captured. The shift from curative medicine to predictive, personalized, and preemptive medicine is also driving an increasing demand for POC molecular diagnostics. This shift, coupled with advances in the field of biosensors, smartphones, wearables, and lab-on-a-chip, is expected to improve the market. For instance, the lab-on-a-chip diagnostics system is formed based on the disposable, single-use, credit card sized, plastic cassette that hosts a microfluidic network for sample processing and analysis. Hence, several companies are adopting this advancement to broaden their product and service portfolios.

Based on application, the infectious diseases segment held the largest market share of more than 45% in 2018 and is expected to continue dominating the market during the forecast period. Geographically, the Americas led the global POC molecular diagnostics market in 2018 with a share of around 56%, followed by the EMEA and APAC. The Americas is expected to continue dominating the market during the forecast period.

Related Links:
Technavio Research


Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
CBM Analyzer
Complete Blood Morphology (CBM) Analyzer
Hemodynamic System Monitor
OptoMonitor
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The Elecsys pTau-181 test helps rule out Alzheimer’s disease in symptomatic patients aged 55 and older by identifying absence of amyloid pathology (photo courtesy of Roche)

Simple Blood Test Offers New Path to Alzheimer’s Assessment in Primary Care

Timely evaluation of cognitive symptoms in primary care is often limited by restricted access to specialized diagnostics and invasive confirmatory procedures. Clinicians need accessible tools to determine... Read more

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Pathology

view channel
Image: The innovative classifier can guide treatment for PDAC and other immunotherapy-resistant cancers (Photo courtesy of Adobe Stock))

Single Sample Classifier Predicts Cancer-Associated Fibroblast Subtypes in Patient Samples

Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, in part because of its dense tumor microenvironment that influences how tumors grow and respond to treatment.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.